Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes

被引：0
|
作者：
Freeman, D.
King, C. R.
机构：
[1] Naples Radiat Oncol PA, Naples, FL USA
[2] Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles Sch Med, Los Angeles, CA 90024 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 07期
关键词：
D O I：
10.1200/jco.2011.29.7_suppl.94
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
94
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes
    Debra E Freeman
    Christopher R King
    [J]. Radiation Oncology, 6
  • [2] Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes
    Freeman, Debra E.
    King, Christopher R.
    [J]. RADIATION ONCOLOGY, 2011, 6
  • [3] Five-year Outcome of Stereotactic Hypofractionated Accurate Radiotherapy of the Prostate (SHARP) for Patients with Low-risk Prostate Cancer
    Pham, H. T.
    Song, G.
    Badiozamani, K.
    Yao, M.
    Corman, J.
    Hsi, R. A.
    Madsen, B.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S58 - S58
  • [4] Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer
    Zelefsky, Michael J.
    Kollmeier, Marisa
    McBride, Sean
    Varghese, Melissa
    Mychalczak, Borys
    Gewanter, Richard
    Garg, Madhur K.
    Happersett, Laura
    Goldman, Debra A.
    Pei, Isaac
    Lin, Mary
    Zhang, Zhigang
    Cox, Brett W.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01): : 42 - 49
  • [5] Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
    Kishan, Amar U.
    Dang, Audrey
    Katz, Alan J.
    Mantz, Constantine A.
    Collins, Sean P.
    Aghdam, Nima
    Chu, Fang-I
    Kaplan, Irving D.
    Appelbaum, Limor
    Fuller, Donald B.
    Meier, Robert M.
    Loblaw, D. Andrew
    Cheung, Patrick
    Pham, Huong T.
    Shaverdian, Narek
    Jiang, Naomi
    Yuan, Ye
    Bagshaw, Hilary
    Prionas, Nicolas
    Buyyounouski, Mark K.
    Spratt, Daniel E.
    Linson, Patrick W.
    Hong, Robert L.
    Nickols, Nicholas G.
    Steinberg, Michael L.
    Kupelian, Patrick A.
    King, Christopher R.
    [J]. JAMA NETWORK OPEN, 2019, 2 (02)
  • [6] Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma
    McBride, Sean M.
    Wong, Douglas S.
    Dombrowski, John J.
    Harkins, Bonnie
    Tapella, Patricia
    Hanscom, Heather N.
    Collins, Sean P.
    Kaplan, Irving D.
    [J]. CANCER, 2012, 118 (15) : 3681 - 3690
  • [7] Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial
    See, Andrew W.
    Conway, Paul
    Frydenberg, Mark
    Haxhimolla, Hodo
    Costello, Anthony J.
    Moon, Daniel
    Ruljancich, Paul
    Grummet, Jeremy
    Pranavan, Ganes
    Peters, Justin
    Smyth, Lloyd M. L.
    Gwini, Stella M.
    Mckenzie, Dean P.
    Bowden, Patrick
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2024, 155 (07) : 1248 - 1256
  • [8] Five-Year Outcomes From a Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
    Meier, R.
    Beckman, A.
    Henning, G.
    Mohideen, N.
    Woodhouse, S. A.
    Cotrutz, C.
    Kaplan, I. D.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S33 - S34
  • [9] Stereotactic body radiotherapy for low and intermediate risk prostate cancer: Four-year outcomes.
    Potharaju, Mahadev
    Ravishankar, L. S.
    Sasikumar, Neetu
    Sadiq, A. L., I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] LONG-TERM OUTCOMES FROM A PROSPECTIVE TRIAL OF STEREOTACTIC BODY RADIOTHERAPY FOR LOW-RISK PROSTATE CANCER
    King, Christopher R.
    Brooks, James D.
    Gill, Harcharan
    Presti, Joseph C., Jr.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (02): : 877 - 882
12345